Fresh Series A backs a hybrid model blending hum

Jupiter Neurosciences, Inc.

Gameto, a clinical‑stage biotechnology company

Acorn Biolabs said it has treated the first patie

New funding taps human-brain data to track a pro

Death Clock adds AI-powered blood biomarker anal

As psychedelics emerge as tools for cognitive re

Big pharma AstraZeneca partners with Hong Kong’s CSPC to develop next-gen weight management drugs worldwide. Managing your weight is possible without complicated schedules, multiple pills or daily injections. That’s the vision British-Swedish pharma giant AstraZeneca is chasing with its latest move: a massive $18.5 billion licensing deal with Hong Kong-based CSPC Pharmaceutical Group to develop and commercialize cutting-edge obesity drugs outside China, Hong Kong, Macao and Taiwan [1]. The core of the deal is SYH2082, an injectable drug candidate that’s ready for clinical trials, along with several other programs designed to make weight loss more consistent, effective and patient-friendly. AstraZeneca is paying $1.2 billion upfront, with the potential for another $17.3 billion if the treatments hit development and sales milestones. “This strategic collaboration advances our weight management portfolio by delivering novel assets which complement our existing programmes,” said Sharon Barr, PhD, AstraZeneca’s head of biopharmaceuticals R&D [1]. “It will provide access to CSPC’s proprietary AI-enabled peptide capabilities and platform technology, which have the potential to transform the treatment of obesity.” Obesity isn’t just about fitting into your favorite jeans. It’s a silent contributor to conditions that shave years off our lives, like type 2 diabetes, heart disease and certain chronic…

First patient dosing signals growing confidence

Pre-seed funding will help Xella build tools tha

From peptides to stem cells, a physician shows h

Preclinical results spotlight a new AI-driven ap

New research maps the slow cascade from brief ta

Company initially targets ‘exosome-based welln

Drug could offer weekly at-home injections, simp

Mesoblast Limited, a global developer of allogene

ProMIS Neurosciences Inc.

NeuroEM Therapeutics, a clinical-stage biotechnol

Illumina, Inc.

GenSight Biologics S.A.

Fractyl Health, Inc.

A commentary issued on behalf of VentriPoint Diag

Alterity Therapeutics Ltd.

Correcting for extrinsic mortality suggests intr

Corsera COO explains why the biotech is building

Altimmune raises $75 million to advance pemvidut

PMD trial ties functional measures with NAD⁺ a

Juvenescence-backed biotech targets ‘continuou

The global autologous cell therapy market—thera

The global autologous cell therapy market—thera

The DUB (deubiquitinase) inhibitors market is exp

Insilico Medicine, a generative artificial intell

Repare Therapeutics Inc.

Bexorg Inc.

Funding to support commercial launch and continu

A brain aging study is catching the attention of

As shares rebound, investors are weighing whethe

A landmark brain study suggests severe CTE shoul

The Am Law 100 firm launches a dedicated group t

Mesoblast Limited reported that early real‑worl

Genflow Biosciences Plc, a UK‑based biotechnolo

Sensorion SA, a clinical-stage biotechnology comp

Higginbotham, an employee-owned insurance and fin

Insilico Medicine, a clinical‑stage biotechnolo

The personalized ophthalmology therapies market i

StarkAge Therapeutics, a French biotechnology com

New membership-based service at Raffles Hotel Ar

Personalized nutrition pioneer brings 3D-printed

A milestone moment for longevity as Life Bioscie

Insilico Medicine and Qilu Pharmaceutical team u